Claire Boyle

Chair and Non-Executive Director

Read more
Claire was appointed as a Director of the Company on 14 October 2021.

Claire is a non-executive director and chair of the audit committee of Fidelity Special Values Plc and Aberdeen Japan Investment Trust PLC and a non-executive director of The Monks Investment Trust. She has over 20 years’ experience working in financial services and investment management, having qualified as a chartered accountant with Coopers and Lybrand, where she specialised in litigation support and forensic accounting. Claire then spent thirteen years working in equity investment management for Robert Fleming Investment Management, American Express Asset Management and latterly Oxburgh Partners, where she was a partner with responsibility for their European Hedge Fund. Claire has a degree in Natural Sciences from Durham University.

Dr Sally Ann Forsyth OBE

Non-Executive Director and Sustainability Lead

Read more
Sally Ann was appointed as a Director of the Company on 14 October 2021.

Sally Ann is CEO of the Stevenage Bioscience Catalyst and is a pioneer of the Life Science real estate industry with 16 years of experience in the delivery of outstanding science parks.  She has been responsible for the strategy, growth and development of four internationally recognised clusters including Harwell Oxford, Colworth Science Park, Norwich Research Park and most recently Stevenage Bioscience Catalyst where she is CEO. She began her career with Unilever where she had lead responsibility for scientific Strategic Alliances and Open Innovation and gained an insight into the needs of growing companies as part of the founding team of Unilever Ventures.  She gained her property experience through Goodman International where she was Director of Science Parks responsible for the development and management of their UK portfolio. She has a PhD in molecular biology from the University of Cambridge, a certificate in Real Estate Economics and Finance from LSE and is a qualified management accountant (CGMA). She was awarded an OBE for services to Business and Science in 2021.

Mike Taylor

Non-Executive Director

Read more
Mike was appointed as a Director of the Company on 14 October 2021.

Mike is Commercial Director for the British Heart Foundation (the “BHF”), where he is responsible for their commercial revenues across 720 retail outlets, online channels and commercial health ventures, with annual revenues of over £200M. The BHF funds Life Science research into heart and circulatory diseases. Prior to this, he was MD at a number of national retailers, including Budgens, Londis and Whittard. Mike has a degree in Economics from UEA.

Claire was appointed as a Director of the Company on 14 October 2021.

Claire is a non-executive director and chair of the audit committee of Fidelity Special Values Plc and Aberdeen Japan Investment Trust PLC and a non-executive director of The Monks Investment Trust. She has over 20 years’ experience working in financial services and investment management, having qualified as a chartered accountant with Coopers and Lybrand, where she specialised in litigation support and forensic accounting. Claire then spent thirteen years working in equity investment management for Robert Fleming Investment Management, American Express Asset Management and latterly Oxburgh Partners, where she was a partner with responsibility for their European Hedge Fund. Claire has a degree in Natural Sciences from Durham University.

Sally Ann was appointed as a Director of the Company on 14 October 2021.

Sally Ann is CEO of the Stevenage Bioscience Catalyst and is a pioneer of the Life Science real estate industry with 16 years of experience in the delivery of outstanding science parks.  She has been responsible for the strategy, growth and development of four internationally recognised clusters including Harwell Oxford, Colworth Science Park, Norwich Research Park and most recently Stevenage Bioscience Catalyst where she is CEO. She began her career with Unilever where she had lead responsibility for scientific Strategic Alliances and Open Innovation and gained an insight into the needs of growing companies as part of the founding team of Unilever Ventures.  She gained her property experience through Goodman International where she was Director of Science Parks responsible for the development and management of their UK portfolio. She has a PhD in molecular biology from the University of Cambridge, a certificate in Real Estate Economics and Finance from LSE and is a qualified management accountant (CGMA). She was awarded an OBE for services to Business and Science in 2021.

Mike was appointed as a Director of the Company on 14 October 2021.

Mike is Commercial Director for the British Heart Foundation (the “BHF”), where he is responsible for their commercial revenues across 720 retail outlets, online channels and commercial health ventures, with annual revenues of over £200M. The BHF funds Life Science research into heart and circulatory diseases. Prior to this, he was MD at a number of national retailers, including Budgens, Londis and Whittard. Mike has a degree in Economics from UEA.

Richard Howell

Senior Independent Non-Executive Director

Read more
Richard was appointed as a Director of the Company on 3 May 2022.

Richard is the Chief Financial Officer of Primary Health Properties plc, the FTSE-250 REIT and leading investor in flexible, modern primary healthcare accommodation across the UK and Ireland. He has over 25 years of commercial property experience within the listed property sector and previously held the role of Finance Director – Joint Ventures at LondonMetric Property plc until March 2017. Whilst working for LondonMetric Property plc and Brixton plc, he was involved in over £5 billion of property transactions. Richard is a qualified accountant and has a degree in Accounting and Finance from Kingston University.

Richard was appointed as a Director of the Company on 3 May 2022.

Richard is the Chief Financial Officer of Primary Health Properties plc, the FTSE-250 REIT and leading investor in flexible, modern primary healthcare accommodation across the UK and Ireland. He has over 25 years of commercial property experience within the listed property sector and previously held the role of Finance Director – Joint Ventures at LondonMetric Property plc until March 2017. Whilst working for LondonMetric Property plc and Brixton plc, he was involved in over £5 billion of property transactions. Richard is a qualified accountant and has a degree in Accounting and Finance from Kingston University.

Download the matters reserved for the Board

Download the responsibilities of the chair of the Board

Disclaimer

IMPORTANT NOTICE: VIEWING THE MATERIALS YOU SEEK TO ACCESS MAY NOT BE LAWFUL IN CERTAIN JURISDICTIONS.  IN OTHER JURISDICTIONS, ONLY CERTAIN CATEGORIES OF PERSON MAY BE ALLOWED TO VIEW SUCH MATERIALS.  ANY PERSON WHO WISHES TO VIEW THESE MATERIALS MUST FIRST SATISFY THEMSELVES THAT THEY ARE NOT SUBJECT TO ANY LOCAL REQUIREMENTS THAT PROHIBIT OR RESTRICT THEM FROM DOING SO.

THE MATERIALS CONTAINED HEREIN ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, TO U.S. PERSONS OR IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OR OTHER JURISDICTION OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA), AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.

The information and materials contained herein (the “Website Materials“) are exclusively intended for persons who are not residents of the United States and who are not physically present in the United States. The information contained herein and on the pages that follow does not constitute an offer of securities for sale or a solicitation of an offer to purchase securities in the United States or in any jurisdiction or jurisdictions in which such offers or sales are unlawful. The shares of Life Science REIT plc (the “Company“) have not been nor will they be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act“), or with any securities regulatory authority of any state or other jurisdiction of the United States and may not be offered, sold, resold, pledged, taken up, exercised, renounced, transferred, delivered or distributed, directly or indirectly, within the United States or to or for the account or benefit of U.S. Persons (as defined in Regulation S of the Securities Act) except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. There will be no public offer of the securities in the United States, Australia, Canada, Japan or the Republic of South Africa or any jurisdiction in which such an offer would constitute violation of the relevant laws or regulations of such jurisdiction. The Company will not be registered under the U.S. Investment Company Act of 1940, as amended (the “Investment Company Act”), and investors will not be entitled to the benefits of the Investment Company Act.

Subject to certain exceptions, the securities referred to herein and on the pages that follow may not be offered, sold, resold, taken up, exercised, renounced, transferred, delivered or distributed, directly or indirectly, in Australia, Canada, Japan, the Republic of South Africa or any jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction or to any resident or citizen of Australia, Canada, Japan or the Republic of South Africa. No offer and sale of the securities referred to herein and on the pages that follow has been or will be registered under the applicable securities laws of Australia, Canada, Japan or the Republic of South Africa.

In addition, the securities referred to herein and on the pages that follow may only be offered: (i) in the United Kingdom (“UK“), to the extent that the securities are permitted to be marketed in the UK pursuant to the Alternative Investment Fund Managers Directive (Directive 2011/ (61/EU) (“AIFMD“) as implemented in the UK by UK statutory instruments and by virtue of the European Union (Withdrawal) Act 2018, and in any EEA jurisdiction to the extent that such securities are permitted to be marketed into the relevant EEA jurisdiction pursuant to the AIFMD (and/or any applicable local implementing measures); or (ii) can otherwise be lawfully offered or sold (including on the basis of an unsolicited request from a ‘professional investor’ (as that term is used in the AIFMD)).

Any person accessing the Website Materials in any other jurisdiction should inform themselves about and observe any applicable legal requirements in their jurisdiction.

Any person accessing the Website Materials should carefully review the Terms and Conditions of this website. By using the Website Materials, you indicate that you accept the Terms and Conditions and that you agree to abide by them. The Company may change the Terms and Conditions at any time. Such changes will be posted on this website. Your access to this website is governed by the version of the Terms and Conditions then in force. If you do not agree to the Terms and Conditions, please refrain from using this website.

By clicking ‘I understand and agree’ below, you represent, warrant and agree that:

YOU ARE NOT INVESTING OR OTHERWISE ACTING FOR THE ACCOUNT OR BENEFIT OF A U.S. PERSON OR A RESIDENT OF AUSTRALIA, CANADA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA; AND

YOU ARE NOT A U.S. PERSON OR OTHERWISE A RESIDENT OF AUSTRALIA, CANADA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA; AND

YOU ARE NOT IN THE UNITED STATES OR IN ANY OTHER JURISDICTION WHERE ACCESSING THIS WEBSITE MAY BE PROHIBITED BY LAW OR REGULATION; AND

YOU WILL NOT TRANSMIT OR OTHERWISE SEND ANY INFORMATION CONTAINED IN THIS WEBSITE TO ANY PERSONS IN THE UNITED STATES OR WHO ARE U.S. PERSONS OR TO ANY PUBLICATIONS WITH A GENERAL CIRCULATION IN THE UNITED STATES; AND

YOU HAVE READ, UNDERSTOOD AND AGREE TO THE ABOVE.

If you cannot so represent, warrant and agree, you must click the button labelled ‘I decline’ or otherwise exit this website.

Thank you for your interest. Legal restrictions prevent us from allowing you further access to this website.

If you believe you are a resident of, and located in, a jurisdiction where viewing is permitted by law, and you can confirm that to us, please contact [email protected].